Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies

Myeloma patients progressing on BCMA-targeted therapy can maintain BCMA expression and still respond to different BCMA-targeted therapy. These observations suggest this patient population could be included in ongoing BCMA-targeted therapy trials.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood Adv
Hauptverfasser: Cohen, Adam D., Garfall, Alfred L., Dogan, Ahmet, Lacey, Simon F., Martin, Chris, Lendvai, Nikoletta, Vogl, Dan T., Spear, Matthew, Lesokhin, Alexander M.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Hematology 2019
Schlagworte:
Exceptional Case Report
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6712532/
https://ncbi.nlm.nih.gov/pubmed/31451444
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000466
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge